Ultrashort Cationic Lipopeptides and Lipopeptoids Selectively Induce Cytokine Production in Macrophages

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Findlay, Brandon ^a   Mookherjee, Neeloffer ^b   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; ANTIINFECTIVE AGENT; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHEMOKINE; CHEMOKINE GRO ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPEPTIDE; LIPOPEPTIDE DERIVATIVE; LIPOPEPTOID DERIVATIVE; PEPTOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LIPID ANALYSIS; MACROPHAGE ACTIVATION; STRUCTURE ACTIVITY RELATION;

ANTIMICROBIAL CATIONIC PEPTIDES; CELL DIFFERENTIATION; CELL LINE; CHEMOKINE CXCL1; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; LIPOPEPTIDES; MACROPHAGES; MOLECULAR STRUCTURE; MONOCYTES; PEPTOIDS; PROTEIN STABILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE-ACTIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873497595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054280     Document Type: Article

References (40)

1. Tadesse DA, Zhao S, Tong E, Ayers S, Singh A, et al. (2012) Antimicrobial drug resistance in escherichia coli from humans and food animals, united states, 1950-2002. Emerging Infectious Diseases 18: 741-749.
2. Hammerum AM, Heuer OE, Emborg HD, Bagger-Skjot L, Jensen VF, et al. (2007) Danish integrated antimicrobial resistance monitoring and research program. Emerging Infectious Diseases 13: 1632-1639.
3. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nature Reviews.Drug Discovery 6: 29-40.
4. Yeung AT, Gellatly SL, Hancock RE, (2011) Multifunctional cationic host defence peptides and their clinical applications. Cellular and Molecular Life Sciences: CMLS 68: 2161-2176.
5. Zasloff M, (1987) Magainins, a class of antimicrobial peptides from xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proceedings of the National Academy of Sciences of the United States of America 84: 5449-5453.
6. Khandelia H, Ipsen JH, Mouritsen OG, (2008) The impact of peptides on lipid membranes. Biochimica Et Biophysica Acta 1778: 1528-1536.
7. Yang L, Gordon VD, Trinkle DR, Schmidt NW, Davis MA, et al. (2008) Mechanism of a prototypical synthetic membrane-active antimicrobial: Efficient hole-punching via interaction with negative intrinsic curvature lipids. Proceedings of the National Academy of Sciences of the United States of America 105: 20595-20600.
8. Ge Y, MacDonald DL, Holroyd KJ, Thornsberry C, Wexler H, et al. (1999) In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrobial Agents and Chemotherapy 43: 782-788.
9. Brogden KA, (2005) Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nature Reviews.Microbiology 3: 238-250.
10. Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, et al. (2010) Peptidomimetic antibiotics target outer-membrane biogenesis in pseudomonas aeruginosa. Science (New York, N.Y.) 327: 1010-1013.
11. Findlay B, Zhanel GG, Schweizer F, (2010) Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrobial Agents and Chemotherapy 54: 4049-4058.
12. Kaoud TS, Mitra S, Lee S, Taliaferro J, Cantrell M, et al. (2011) Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chemical Biology 6: 658-666.
13. Czihal P, Knappe D, Fritsche S, Zahn M, Berthold N, et al. (2012) Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant gram-negative pathogens. ACS Chemical Biology 7: 1281-1291.
14. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, et al. (1995) Human CAP18: A novel antimicrobial lipopolysaccharide-binding protein. Infection and Immunity 63: 1291-1297.
15. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, et al. (2005) Impact of LL-37 on anti-infective immunity. Journal of Leukocyte Biology 77: 451-459.
16. Larrick JW, Hirata M, Zhong J, Wright SC, (1995) Anti-microbial activity of human CAP18 peptides. Immunotechnology: An International Journal of Immunological Engineering 1: 65-72.
17. Choi KY, Mookherjee N, (2012) Multiple immune-modulatory functions of cathelicidin host defense peptides. Frontiers in Immunology 3: 149.
18. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, et al. (2003) The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. The Journal of Investigative Dermatology 120: 379-389.
19. Scott MG, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, et al. (2007) An anti-infective peptide that selectively modulates the innate immune response. Nature Biotechnology 25: 465-472.
20. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, et al. (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. Journal of Immunology (Baltimore, Md.: 1950) 184: 2539-2550.
21. Hancock RE, Nijnik A, Philpott DJ, (2012) Modulating immunity as a therapy for bacterial infections. Nature Reviews.Microbiology 10: 243-254.
22. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, et al. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. The Journal of Experimental Medicine 192: 1069-1074.
23. Mookherjee N, Lippert DN, Hamill P, Falsafi R, Nijnik A, et al. (2009) Intracellular receptor for human host defense peptide LL-37 in monocytes. Journal of Immunology (Baltimore, Md.: 1950) 183: 2688-2696.
24. Thwaite JE, Hibbs S, Titball RW, Atkins TP, (2006) Proteolytic degradation of human antimicrobial peptide LL-37 by bacillus anthracis may contribute to virulence. Antimicrobial Agents and Chemotherapy 50: 2316-2322.
25. Thaker HD, Som A, Ayaz F, Lui D, Pan W, et al. (2012) Synthetic mimics of antimicrobial peptides with immunomodulatory responses. Journal of the American Chemical Society 134: 11088-11091.
26. Makovitzki A, Baram J, Shai Y, (2008) Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: In vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 47: 10630-10636.
27. Findlay B, Zhanel GG, Schweizer F, (2012) Investigating the antimicrobial peptide "Window of activity" using cationic lipopeptides with hydrocarbon and fluorinated tails. Int J Antimicrob Agents 40: 36-42.
28. Findlay B, Szelemej P, Zhanel GG, Schweizer F, (2012) Guanidylation and tail effects in cationic antimicrobial lipopeptoids. PloS One 7: e41141.
29. Henzler-Wildman KA, Martinez GV, Brown MF, Ramamoorthy A, (2004) Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry 43: 8459-8469.
30. Simon RJ, Kania RS, Zuckermann RN, Huebner VD, Jewell DA, et al. (1992) Peptoids: A modular approach to drug discovery. Proceedings of the National Academy of Sciences of the United States of America 89: 9367-9371.
31. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. Journal of Immunology (Baltimore, Md.: 1950) 176: 2455-2464.
32. Mookherjee N, Hamill P, Gardy J, Blimkie D, Falsafi R, et al. (2009) Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Molecular bioSystems 5: 483-496.
33. Jin T, Xu X, Hereld D, (2008) Chemotaxis, chemokine receptors and human disease. Cytokine 44: 1-8.
34. Turner-Brannen E, Choi KY, Arsenault R, El-Gabalawy H, Napper S, et al. (2011) Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1. Journal of Immunology (Baltimore, Md.: 1950) 186: 7127-7135.
35. Kumar H, Kawai T, Akira S, (2011) Pathogen recognition by the innate immune system. International Reviews of Immunology 30: 16-34.
36. Agnihotri G, Crall BM, Lewis TC, Day TP, Balakrishna R, et al. (2011) Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides. Journal of Medicinal Chemistry 54: 8148-8160.
37. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, et al. (2001) Discrimination of bacterial lipoproteins by toll-like receptor 6. International Immunology 13: 933-940.
38. Bradley JR, (2008) TNF-mediated inflammatory disease. The Journal of Pathology 214: 149-160.
39. Yu J, Mookherjee N, Wee K, Bowdish DM, Pistolic J, et al. (2007) Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. Journal of Immunology (Baltimore, Md.: 1950) 179: 7684-7691.
40. Baker TJ, Luedtke NW, Tor Y, Goodman M, (2000) Synthesis and anti-HIV activity of guanidinoglycosides. The Journal of Organic Chemistry 65: 9054-9058.